CA3154192A1 - Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy - Google Patents
Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy Download PDFInfo
- Publication number
- CA3154192A1 CA3154192A1 CA3154192A CA3154192A CA3154192A1 CA 3154192 A1 CA3154192 A1 CA 3154192A1 CA 3154192 A CA3154192 A CA 3154192A CA 3154192 A CA3154192 A CA 3154192A CA 3154192 A1 CA3154192 A1 CA 3154192A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- cells
- melanoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913571P | 2019-10-10 | 2019-10-10 | |
| US62/913,571 | 2019-10-10 | ||
| PCT/US2020/055121 WO2021072300A1 (en) | 2019-10-10 | 2020-10-09 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3154192A1 true CA3154192A1 (en) | 2021-04-15 |
Family
ID=75436788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154192A Pending CA3154192A1 (en) | 2019-10-10 | 2020-10-09 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12496346B2 (https=) |
| EP (1) | EP4041718A4 (https=) |
| JP (1) | JP7631329B2 (https=) |
| KR (1) | KR20220080139A (https=) |
| CN (1) | CN114761389B (https=) |
| AU (1) | AU2020361679B2 (https=) |
| BR (1) | BR112022006739B1 (https=) |
| CA (1) | CA3154192A1 (https=) |
| IL (1) | IL291979B2 (https=) |
| MX (1) | MX2022004341A (https=) |
| WO (1) | WO2021072300A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095515A1 (en) | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| BR112022006739B1 (pt) | 2019-10-10 | 2024-01-23 | Cellectar Biosciences, Inc | Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer |
| WO2025073824A1 (en) * | 2023-10-03 | 2025-04-10 | Aarhus Universitet | Phospholipid conjugates and their uses |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965391A (en) | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| DE4132344A1 (de) | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| DE4408011C1 (de) | 1994-03-10 | 1995-11-02 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Tumortherapie |
| CA2276284C (en) | 1996-12-04 | 2006-10-10 | The Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
| US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| ATE437657T1 (de) | 2004-03-02 | 2009-08-15 | Cellectar Inc | Phospholipid-analoga für die behandlung von krebs |
| US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| US7632644B2 (en) | 2004-03-02 | 2009-12-15 | Cellectar, Inc. | Imaging and selective retention of phospholipid ether analogs |
| EP1773408A2 (en) | 2004-07-08 | 2007-04-18 | Cellectar, Llc | Virtual colonoscopy with radiolabeled phospholipid ether analogs |
| MX2007007497A (es) | 2004-12-20 | 2008-01-11 | Cellectar Llc | Analogos de fosfolipido eter para la deteccion y tratamiento del cancer. |
| UA99434C2 (ru) | 2005-12-19 | 2012-08-27 | Аетерна Центаріс Гмбх | Применение производных алкилфосфолипидов со сниженной цитотоксичностью |
| US7893286B2 (en) | 2007-06-01 | 2011-02-22 | Cellectar, Inc. | Method for the synthesis of phospholipid ethers |
| US8022235B2 (en) | 2007-06-01 | 2011-09-20 | Cellectar, Inc. | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
| EP2222278B1 (en) | 2007-11-28 | 2015-04-08 | Celator Pharmaceuticals, Inc. | Improved taxane delivery system |
| US20100120727A1 (en) | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| US20100286510A1 (en) | 2009-05-11 | 2010-11-11 | Pinchuk Anatoly | Use of fluorescent phospholipid ether compounds in biopsies |
| ES2549459T3 (es) | 2009-05-11 | 2015-10-28 | Cellectar, Inc. | Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso |
| US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
| US7811548B1 (en) | 2009-05-11 | 2010-10-12 | Cellectar, Inc. | Fluorescent phospholipid ether compounds and compositions |
| JP6092624B2 (ja) | 2009-06-12 | 2017-03-08 | セレクター，インコーポレイティド | 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物 |
| WO2011031919A2 (en) | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Non-radioactive phospholipid compounds, compositions, and methods of use |
| US20140255432A1 (en) * | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| WO2014106826A2 (en) | 2013-01-07 | 2014-07-10 | Piramal Enterprises Limited | Anthracycline analogue and uses thereof |
| FR3023290B1 (fr) | 2014-07-04 | 2016-08-19 | Pf Medicament | Derives de flavaglines |
| KR102508023B1 (ko) | 2014-09-03 | 2023-03-10 | 이뮤노젠 아이엔씨 | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 |
| CA2968145C (en) | 2014-11-17 | 2023-06-27 | Cellectar Biosciences, Inc. | Phospholipid ether analogs as cancer-targeting drug vehicles |
| DK3888658T3 (da) | 2015-11-25 | 2024-03-18 | Effector Therapeutics Inc | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil |
| EP3439666A4 (en) | 2016-05-20 | 2019-12-11 | The University of Chicago | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF |
| WO2017214024A1 (en) * | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| WO2017218702A1 (en) | 2016-06-14 | 2017-12-21 | Cellectar Biosciences, Inc. | Phospholipid ether analogs for the identification and isolation of circulating tumor cells |
| US11286281B2 (en) | 2017-05-10 | 2022-03-29 | Zealand Pharma A/S | Homodetic cyclic peptides targeting alpha-4-beta-7 integrin |
| US11167050B2 (en) | 2017-09-26 | 2021-11-09 | National University Corporation Chiba University | Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound |
| JP7491572B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| CA3095515A1 (en) * | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| SG11202009990UA (en) | 2018-04-16 | 2020-11-27 | Nihon Mediphysics Co Ltd | Modified antibody and radioactive metal-labelled antibody |
| NZ786360A (en) * | 2019-09-12 | 2025-12-19 | Cellectar Biosciences Inc | Phospholipid ether conjugates as cancer-targeting drug vehicles |
| BR112022006739B1 (pt) | 2019-10-10 | 2024-01-23 | Cellectar Biosciences, Inc | Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer |
-
2020
- 2020-10-09 BR BR112022006739-9A patent/BR112022006739B1/pt active IP Right Grant
- 2020-10-09 MX MX2022004341A patent/MX2022004341A/es unknown
- 2020-10-09 EP EP20875069.5A patent/EP4041718A4/en active Pending
- 2020-10-09 US US17/768,429 patent/US12496346B2/en active Active
- 2020-10-09 CA CA3154192A patent/CA3154192A1/en active Pending
- 2020-10-09 KR KR1020227015216A patent/KR20220080139A/ko active Pending
- 2020-10-09 JP JP2022521432A patent/JP7631329B2/ja active Active
- 2020-10-09 IL IL291979A patent/IL291979B2/en unknown
- 2020-10-09 CN CN202080081971.7A patent/CN114761389B/zh active Active
- 2020-10-09 AU AU2020361679A patent/AU2020361679B2/en active Active
- 2020-10-09 WO PCT/US2020/055121 patent/WO2021072300A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022551495A (ja) | 2022-12-09 |
| BR112022006739A2 (pt) | 2022-06-28 |
| BR112022006739B1 (pt) | 2024-01-23 |
| IL291979B2 (en) | 2025-12-01 |
| KR20220080139A (ko) | 2022-06-14 |
| AU2020361679A1 (en) | 2022-04-28 |
| EP4041718A4 (en) | 2023-12-20 |
| CN114761389A (zh) | 2022-07-15 |
| EP4041718A1 (en) | 2022-08-17 |
| IL291979B1 (en) | 2025-08-01 |
| US20240325545A1 (en) | 2024-10-03 |
| CN114761389B (zh) | 2025-02-07 |
| MX2022004341A (es) | 2022-08-10 |
| JP7631329B2 (ja) | 2025-02-18 |
| WO2021072300A1 (en) | 2021-04-15 |
| US12496346B2 (en) | 2025-12-16 |
| AU2020361679B2 (en) | 2026-03-19 |
| IL291979A (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101915452B1 (ko) | 백금 화합물, 조성물 및 이의 용도 | |
| AU2020361679B2 (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| AU2020346898B2 (en) | Phospholipid ether conjugates as cancer-targeting drug vehicles | |
| AU2021261949A1 (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| AU2022246090A1 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| EA047198B1 (ru) | Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии | |
| WO2011009059A2 (en) | Method of treating or preventing cancer | |
| HK40043232B (zh) | 磷脂-flavagline缀合物及将其用於靶向癌症治疗的方法 | |
| CN121969398A (zh) | 抗体偶联药物及其用途 | |
| TR202016160T (tr) | Fosfoli̇pi̇d-flavagli̇n konjügeleri̇ ve bunlarin hedefe yöneli̇k | |
| HK40043232A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| EA053296B1 (ru) | Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак | |
| EA046205B1 (ru) | Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240809 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240809 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241004 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241004 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250331 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250423 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251003 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251003 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260324 |